MedTrace Logo

Concomitant Radio-chemotherapy in the Elderly

NCT01029678 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2018-05-03

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety of non small cell lung cancer (NSCLC) treatment with cisplatin and oral vinorelbine administered weekly associated with concomitant radiotherapy in elderly patients.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

Cisplatin IV

Cisplatin IV 30 mg/m2/ (Day 1, Day 8, Day 15, Day 22, Day 29, Day 36)

DRUG

Vinorelbine

Vinorelbine per os 30 mg/m2/(day1, day8, day15, day22, day29, day36

RADIATION

Radiotherapy

66Gy, 33 fractions, 6 week

Sponsors & Collaborators

  • Pierre Fabre Laboratories

    collaborator INDUSTRY

  • University Hospital, Limoges

    lead OTHER

Principal Investigators

  • Chrystèle LOCHER, MD · CH Meaux

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2015-01-31
Completion
2016-06-30

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01029678 on ClinicalTrials.gov